durect.com (DRRX) - Koefisien utang jangka dawa marang modal

DURECT Corporation operates in the non-cyclical liver therapy sector, where demand for biotechnology renders the asset defensive during recessions. The long-term debt-to-equity ratio confirms financial stability, and 0.20 reflects the latest level of this metric. Business stability is based on proprietary drug delivery methods and active clinical trials of innovative drugs for organ restoration.

This ratio is calculated as the proportion of liabilities with a maturity exceeding one year to the company's total equity. The metric determines the extent to which financial stability depends on long-term borrowing. For DURECT Corporation (DRRX), this is critical when financing larsucosterol trials and protecting patents. Assessing the debt load allows for forecasting the cost of loan servicing. By analyzing the long-term debt-to-equity ratio, an investor can discern the balance between risks and growth potential.